Study on Application Value of Three Serum Tests for Gastric Cancer in Clinical Diagnosis and Disease Assessment
Objective:To study the application value of three serum tests for gastric cancer in clinical diagnosis and disease evaluation.Method:A total of 82 patients with gastric cancer who admitted to Suzhou Pingjiang Hospital from February 2021 to February 2023 were selected as the study group,in addition,80 patients with gastric benign lesions who admitted to the same hospital in the same period were recorded as the benign gastric disease group.The three serum levels of gastric cancer were detected and compared between two groups,and the efficacy of the three serum levels in the diagnosis of gastric cancer was analyzed by receiver operating characteristic(ROC)curve.In addition,three serum levels of gastric cancer in patients with different clinical stages were compared,and the levels of serum tumor markers were compared between two groups.Result:The serum pepsinogen Ⅰ(PGⅠ)and the ratio of pepsinogen Ⅰto pepsinogen Ⅱ(PGⅡ)(PGR)in the study group were(69.03±8.25)ng/mL and(3.38±0.74),respectively,which were lower than(83.52±11.23)ng/mL and(6.73±1.32)in the benign gastric disease group,PGⅡ was(23.19±4.09)ng/mL,which was higher than(15.66±2.45)ng/mL of the benign gastric disease group,the differences were statistically significant(P<0.05).The combined diagnostic efficacy of three serum tests for gastric cancer was better than those of three alone(P<0.001).The serum PGⅠ and PGR in patients with stage Ⅲ,Ⅳ gastric cancer were lower than those with stage Ⅰ,Ⅱ gastric cancer,while serum PGⅡ was higher than those with stage Ⅰ,Ⅱ gastric cancer,the differences were statistically significant(P<0.05).The levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199)in the study group were higher than those in the benign gastric disease group,the differences were statistically significant(P<0.05).Conclusion:The combination of three serum tests for gastric cancer is effective in the diagnosis of gastric cancer,and can provide an objective basis for disease assessment.
万方数据
维普
